



Sobrerera Pharma receives patent approval in the USA

Sobrerera Pharma AB, a Swedish pharmaceutical company developing new therapies for Alcohol Use Disorder (AUD), announces that the United States Patent and Trademark Office (USPTO) has granted a new patent US 11,318,143 further strengthening the Company's Intellectual property position and coverage for the Company's therapeutic drug candidate SO-001.

The decision to grant of the patent titled 'Treatment of Alcohol Use Disorder' covers the use of varenicline in combination with bupropion for the use in treating Alcohol Use Disorders (AUD) and/or treating alcohol risk consumption.

- "We are pleased that this U.S. patent has been granted, further strengthening Sobrerera's intellectual property portfolio for SO-001 says Ann-Charlotte Rosendahl, CEO. The U.S. market is important and the recent approval is a major milestone as we look to further progress the development of SO-001 for the potential treatment of patients suffering from alcohol addiction".

Sobrerera focuses on research and development of new treatments within psychiatry with an initial focus on Alcohol Use Disorder. The drug candidate SO-001 constitutes a new concept in treating AUD, combining two complementary modes of actions, and directing its effect on the dopamine system. Dopamine plays an important role in the reward system and in addictive disorders. Preclinical data has shown promising results and a phase II clinical study in patients with AUD is ongoing.

About Alcohol Use Disorder

Alcohol Use Disorder is a chronic relapsing brain disease characterized by compulsive use of alcohol and the inability to control intake. It is a common and serious health issue globally, and a major cause of mortality and morbidity. AUD It is the third leading preventable cause of death in the United States, and according to the World Health Organization, harmful use of alcohol is responsible for 5.1% of the global burden of disease^{1,2}. New and improved therapies are greatly needed to help patients suffering from Alcohol Use Disorder.

1. National Institute on Alcohol Abuse and Alcoholism. [Click link here](#)
2. World Health Organization. [Click link here](#)

About Sobrerera Pharma AB:

Sobrerera Pharma AB is a clinical stage pharmaceutical company developing new treatments for patients with substance use disorders. The company's initial focus is the product SO-001. A phase II development is ongoing in patients with moderate to severe Alcohol Use Disorder. Alcohol addiction is a major global health issue and a major cause of mortality and morbidity. Sobrerera's vision is to offer an effective and easy to use treatment to improve health and quality of life, to reduce the risk of morbidity and premature death in patients with substance use disorders, and to reduce the related societal costs. The company is headquartered in Gothenburg, Sweden.

More information at:

www.sobrerera.com



Contact:

Ann-Charlotte Rosendahl

CEO, Sobrerera Pharma

ann-charlotte.rosendahl@sobrerera.com

Tel:+46 (0)732 - 096 405